| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | - | 0 | - | - |
| Research and development costs | 50,696 | 60,648 | 91,457 | 361,630 |
| Other costs and expenses | - | - | - | 293,158 |
| Legal fees relating to patents and licensing | - | - | - | 45,416 |
| General and administrative costs | 1,750,658 | 714,161 | 615,483 | 283,053 |
| Total costs and expenses | 1,801,354 | 774,809 | 706,940 | 983,257 |
| Loss from operations | -1,801,354 | -774,809 | -706,940 | -983,257 |
| Foreign currency gain | - | 581 | 79 | -3,161 |
| Interest income | 4,430 | 365 | 441 | 1,437 |
| Interest expense | 457 | 1,810 | 3,135 | 1,049 |
| Unrealized gain (loss) on digital assets | -182,887 | - | - | - |
| Realized gain (loss) on foreign currency transactions | -130 | - | - | - |
| Net loss | -1,980,398 | -775,673 | -709,555 | -986,030 |
| Series b convertible preferred stock 8 cumulative dividend | -50,367 | - | - | - |
| Net loss attributable to common stockholders | -2,030,765 | - | - | - |
| Net loss per common share basic | -0.33 | -0.29 | -0.29 | -0.44 |
| Net loss per common share diluted | -0.33 | -0.29 | -0.29 | -0.44 |
| Weighted average common shares outstanding basic | 6,171,195 | 2,720,533 | 2,471,513 | 2,249,290 |
| Weighted average common shares outstanding diluted | 6,171,195 | 2,720,533 | 2,471,513 | 2,249,290 |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)